Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

1(33.3%)

N/A

1(33.3%)

Phase 2

1(33.3%)

3Total

Phase 3(1)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT06032611Not ApplicableUnknown

Interest of Two Digital Devices for the Diagnosis of Neurocognitive Disorders in Elderly People With Cognitive Symptoms.

Role: collaborator

NCT04113226Phase 2Unknown

Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma

Role: collaborator

NCT02464488Completed

New Oral Direct Anticoagulants in Patients 80 Years Old and Over : a Population Pharmacokinetics Study

Role: lead

NCT01724827Phase 3Completed

Ceramic Versus Composite in the Treatment of Posterior Teeth by Inlays or Onlays

Role: collaborator

All 4 trials loaded